Cover Image
市場調查報告書

杉樹花粉過敏:開發中產品分析

Cedar Pollen Allergy - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 257823
出版日期 內容資訊 英文 47 Pages
訂單完成後即時交付
價格
Back to Top
杉樹花粉過敏:開發中產品分析 Cedar Pollen Allergy - Pipeline Review, H2 2016
出版日期: 2016年09月28日 內容資訊: 英文 47 Pages
簡介

杉樹過敏,是對山間的杉樹產生的花粉產生的過敏反應的季節性過敏。症狀中,包含鼻涕,眼睛發癢,眼淚,鼻塞,及噴嚏等。患者中也有人會疲勞,輕微頭痛,臉部不舒服,喉嚨痛,部分喪失嗅覺,及耳朵堵塞等。使用抗組織胺藥及充血消除劑(鼻炎藥)治療。

本報告提供杉樹花粉過敏的治療藥的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介等相關的系統性資訊。

目錄

簡介

杉樹花粉過敏概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

各開發中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

開發中的產品:各企業

各開發中的產品:各大學/研究機關

開發治療藥的企業

  • ALK-Abello A/S
  • Anergis SA
  • Circassia Pharmaceuticals Plc
  • Immunomic Therapeutics, Inc.
  • Japan Tobacco Inc.
  • REGiMMUNE Corporation

治療藥的評估

  • 單獨療法的情況
  • 各標的
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AllerJ
  • ASP-4070
  • Drugs for Cedar Pollen Allergy
  • JCC-LAMP-Vax
  • MC-LAMP-Vax
  • RGI-1001
  • standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine
  • TO-206
  • Vaccine for Cedar Pollen Allergy
  • Vaccine for Japanese Cedar Pollen Allergy

開發中產品的最新趨勢

暫停的計劃

產品開發里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8489IDB

Summary

Global Markets Direct's, 'Cedar Pollen Allergy - Pipeline Review, H2 2016', provides an overview of the Cedar Pollen Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cedar Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cedar Pollen Allergy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy
  • The report reviews pipeline therapeutics for Cedar Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Cedar Pollen Allergy therapeutics and enlists all their major and minor projects
  • The report assesses Cedar Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Cedar Pollen Allergy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Cedar Pollen Allergy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cedar Pollen Allergy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cedar Pollen Allergy Overview
  • Therapeutics Development
    • Pipeline Products for Cedar Pollen Allergy - Overview
    • Pipeline Products for Cedar Pollen Allergy - Comparative Analysis
  • Cedar Pollen Allergy - Therapeutics under Development by Companies
  • Cedar Pollen Allergy - Therapeutics under Investigation by Universities/Institutes
  • Cedar Pollen Allergy - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Cedar Pollen Allergy - Products under Development by Companies
  • Cedar Pollen Allergy - Products under Investigation by Universities/Institutes
  • Cedar Pollen Allergy - Companies Involved in Therapeutics Development
    • ALK-Abello A/S
    • Astellas Pharma Inc.
    • Circassia Pharmaceuticals Plc
    • Immunomic Therapeutics, Inc.
    • Japan Tobacco Inc.
    • REGiMMUNE Corporation
  • Cedar Pollen Allergy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ASP-4070 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic for Cedar Pollen Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JCC-LAMP-Vax - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RGI-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TO-206 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Cedar Pollen Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Japanese Cedar Pollen Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cedar Pollen Allergy - Dormant Projects
  • Cedar Pollen Allergy - Product Development Milestones
    • Featured News & Press Releases
      • Aug 07, 2015: ALK's partner for Japan reports positive Phase II/III trial results for Japanese Cedar SLIT-tablet
      • Mar 09, 2015: Immunomic Therapeutics to Present at BIO-Europe Annual Conference
      • Feb 20, 2015: Immunomic Therapeutics to Present Data on Its Proprietary LAMP Vaccine Platform at 2015 American Academy of Allergy, Asthma and Immunology Meeting
      • Apr 24, 2013: Immunomic Therapeutics Announces Interim Data Analysis Of Phase I Study To Treat Japanese Red Cedar Allergy
      • Nov 08, 2012: Immunomic Therapeutics Doses First Patient In Phase I Clinical Trial Of JRC-LAMP-Vax Vaccine To Treat Japanese Red Cedar Allergy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Cedar Pollen Allergy, H2 2016
  • Number of Products under Development for Cedar Pollen Allergy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Cedar Pollen Allergy - Pipeline by ALK-Abello A/S, H2 2016
  • Cedar Pollen Allergy - Pipeline by Astellas Pharma Inc., H2 2016
  • Cedar Pollen Allergy - Pipeline by Circassia Pharmaceuticals Plc, H2 2016
  • Cedar Pollen Allergy - Pipeline by Immunomic Therapeutics, Inc., H2 2016
  • Cedar Pollen Allergy - Pipeline by Japan Tobacco Inc., H2 2016
  • Cedar Pollen Allergy - Pipeline by REGiMMUNE Corporation, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Cedar Pollen Allergy - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Cedar Pollen Allergy, H2 2016
  • Number of Products under Development for Cedar Pollen Allergy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top